Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback